



A CRITICAL REVIEW ON BALACHATURBHADRA CHURNA: AN EFFECTIVE AYURVEDA FORMULATION FOR THE PEDIATRIC AGE

Abhishek Joshi^{1*}, Shrikrishna Rajagopala², and Patel Kalpana S.³

¹Universitas Hindu Indonesia, Denpasar, Bali, Republic of Indonesia

²Department of Bala Roga, All India Institute of Ayurveda, New Delhi

³Department of Kaumarbhritya, IPGT & RA, Gujarat Ayurved University, Jamnagar, Gujarat

*[<dr_abhishekjoshi@yahoo.com>](mailto:dr_abhishekjoshi@yahoo.com)

Abstract

Balachaturbhadrha Churna offers a multitude of health benefits for which it has become so popular prescription by Kaumarbhritya practitioners of Ayurveda. It is a combination of four drugs Musta, Pippali, Ativisha and Karkatashringi. This combination was first mentioned in Chakradatta and has been in practice since a millennium. Many queries have been raised on the usage of Aconite species of drugs recently, thus doubting the safety and efficacy of Balachaturbhadrha Churna. Very few works have been published on Balachaturbhadrha Churna till now. The aim of the present study was to compile and review such available references from classics and research works published on Balachaturbhadrha Churna. Total five studies are published on Balachaturbhadrha Churna, which revalidated the impact of classical guidelines. The research papers revealed standards of Quality Control and pharmacological efficacy of the drug. All the experimental studies revealed that Balachaturbhadrha Churna is having no toxic hazards at very higher Dose levels, proving it safe for therapeutic use. Though certain limitations were observed in these researches, the results can be considered as a lead for further well stratified clinical studies.

Keywords: Balachaturbhadrha Churna, pharmacology, Quality Control, standards, therapeutic use

Introduction

Very few medicaments have been described in Ayurveda specially indicated for their usage in children.

One among them is *Balachaturbhadrha Churna* (BCBC) which is a very popular and a beneficial compound formulation in pediatric usage. It is a

widely practiced formulation that is indicated in respiratory disorders, fever, diarrhoea and vomiting of children (Joshi, *et.al.*, 2013).

The nomenclature of Ayurveda was primarily designed to help a physician select a plant for medicinal purposes. This is divided into three sub-topics named *Nama* (name), *Rupa* (form) and *Yukti jnana* (therapeutic usage), which constitutes the three-tier understanding of *ausadhi* (drug materials) (Viswanathan *et.al.*, 2013). *Bala* means a child, *Chatuhu* means combination of four, and *Bhadra* means which is beneficial or best (Radhakantadeva, 1961). Thus the term *Balachaturbhadra* denotes a combination of four drugs that are meant for use in children. The prefix *Bala* suggests that the combination is specially indicated in children and is potent enough to cure the diseases of the pediatric age group.

India has a rich heritage of traditional herbal medicines. With the emerging interest of the world to adopt and study traditional systems, many opportunities have opened up to take advantage of the potential based on different healthcare systems (WHO, 2000). The Ayurvedic pharmaceutical preparations evolved gradually from a simpler form to more complex forms based on plants and plant mineral combinations. This is the unique feature of herbal treatments, that one plant species can cure a particular disease and also can cure a number of other ailments

in combination with other plant species. The clinical effect also varies with different dosages, forms and modes of administration.

Very few research have been published on *Balachaturbhadra Churna. Ativisha (Aconitum heterophyllum* Wall.), one of the ingredients in this combination has been questioned by modern research industry for its safety. *Aconite* species are reported for its cardiotoxic as well as neurotoxic effects (Chan, 2009) but no studies related to the toxic effect of *Aconitum heterophyllum* Linn. in particular have been reported. Nonetheless the use of this formulation since millennia without reports of any untoward effect itself is a testimony to its safety. Still, an evaluation based on objective controlled experiments and a standardization of various parameters will provide proof for the undoubted usefulness of the drug. In this article an attempt has been made to compile and critically evaluate the ancient classics and recent research publication of the drug *Balachaturbhadra Churna*.

Materials and Methods

Reviews of all references available for *Balachaturbhadra Churna* in classical texts as well as very recent literature were explored. Thorough searches were carried out on internet sources while articles published on *Balachaturbhadra Churna* in various journals were analyzed for

comprehensive understanding of the formulation.

Observations

The observations made from the review are mentioned under various headings as follows.

1. Classical references of BCBC

Balachaturbhadra Churna is mentioned for the first time in the text *Chakradatta* (Chakradatta *et.al.*, 1976). Later period the same reference is found in several text books. The detailed description of references available is shown in table 1.

All the texts have mentioned the same four ingredients. Table 2 shows the constituents of *Balachaturbhadra Churna*. It is a fine powder prepared by mixing equal proportions of *Musta* (*Cyperus rotundus* Linn) rhizome, *Pippali* (*Piper longum* Linn) fruit, *Ativisha* (*Aconitum heterophyllum* Wall.) root and *Karkatashringi* (*Pistacia integerrima* Stew.) gall. It is given in the

treatment of various pediatric diseases like *Jvara* (fever), *Atisara* (diarrhoea), *Svasa* and *Kasa* (respiratory disorders) and *Chardi* (vomiting) (Chakradatta, 1976, Sharma and Vijnana, 2001).

2. Pharmaceutical standardization

Ajazuddin *et.al.* in 2012 carried out investigations to study the physicochemical, phytochemical and spectrophotometric analysis of formulation (Ajazuddin, 2012). The values of percentage loss on drying, angle of repose, Hausner ratio, Carr's index of the lab formulation were calculated as 6.84 ± 0.224 , 27.36, 1.25 and 20 respectively. Total ash, acid insoluble ash and water soluble ash were found 8.148 ± 0.337 , 3.281 ± 0.286 , and 45.602 ± 0.414 respectively. Alcoholic and aqueous extracts of formulations and ingredients were prepared and evaluated for phytochemical analysis and the results of extractive values shows higher alcoholic extractive value ($39.294 \pm$

Table 1. References available for *Balachaturbhadra Churna*

Sr. No.	Name of text books	Reference	Time period
1	<i>Cakradatta</i>	64/22	11 th century A.D.
2	<i>Gadanigraha</i>	11/93	12 th century A.D.
3	<i>Sharangadhar Samhita</i>	6/16	13 th century A.D.
4	<i>Bhavaprakasha</i>	71/151	16 th century A.D.
5	<i>Yogaratanakara</i>	71/39	17 th century A.D.
6	<i>Bhaishajya Ratnaval</i>	71/39	18 th century A.D.
7	<i>Bhaishajya Samhita</i>	7/50	20 th century A.D.
8	<i>Bharat Bhaishajya Ratnakar</i>	7/24	20 th century A.D.
9	<i>Bala Tantra</i>	13/10	20 th century A.D.
10	Ayurvedic formulary of India	part 1/page 92	20 th century A.D.

Table 2. Constituents of *Balachaturbhadra Churna*

Sr. No.	Name of text books	Reference	Time period
1	<i>Cakradatta</i>	64/22	11 th century A.D.
2	<i>Gadanigraha</i>	11/93	12 th century A.D.
3	<i>Sharangadhar Samhita</i>	6/16	13 th century A.D.
4	<i>Bhavaprakasha</i>	71/151	16 th century A.D.

2.226) of formulation depict that alcohol is a better solvent for extraction. Three laboratory batches of formulation and Piper longum powder were estimated for their piperine content against standard piperine solution on double beam UV-Visible spectrophotometer at λ max 342.5 nm.

Shahebaz *et.al.* in 2012 made an attempt to evaluate and compare market formulation with in-house sample of *Balchaturbhadra Churna* by performing physico-chemical screening, phytochemical screening, microscopic characterization and fluorescence analysis (Ghadiyali *et.al.*, 2012). Respective physical parameters observed for standard and market preparation of *Balchaturbhadra Churna* were Bulk Density (gm/ml.) 0.5882 and 0.434, Tap Density (gm/ml) 0.8 and 0.625, Carr's Index 26.47 and 30.43, Hausner's Ratio 1.36 and 1.43 and Angle of Repose 32.32 and 34.43. Morphological study of *Balachaturbhadra Churna* showed fine consistency for standard formulations and very fine for market formulations; colour was brown for standard formulations and greyish brown for market formulation, while

it had a pleasant odour and bitter taste for both the formulations. Quantitative Analysis of microscopic constituent of standard and market formulations of *Balachaturbhadra Churna* observed were 3.43 and 3.24 for Starch Grains, 55.12 and 52.56 for Xylem vessels and it was 170.76 and 176.34 for fibres (length). Screening of phytoconstituents in standard and market formulations of *Balachaturbhadra Churna* showed presence of alkaloids, flavonoids, phenolics, carbohydrates, tannins, Sterols and triterpenoids whereas coumarins and saponins were absent.

Estimation of phytoconstituents in standard and market formulations of *Balachaturbhadra Churna* were respectively 0.107% and 0.096% for Flavonoids, 0.84% and 0.76% for Na⁺ ion salts, 0.62% and 0.38% for K⁺ ion salts, 2.91 % and 3.74 % for Tannins and for Crude fibre content it was 15.5% and 13%. Fluorescence analysis was performed by observing the powder of the standard and market formulation of *Balachaturbhadra Churna* with 1N HCL, 1N H₂SO₄, 1N HNO₃, aqueous and alcoholic NaOH, Iodine solution, KOH and NH₃ and the fluorescence in day light and in UV light was compared

for both the samples. After analysis it was observed that market samples matched exactly with that of authentic standards of in-house formulation after performing the standardization.

Abhishek Joshi *et.al.* in 2013 made an attempt to develop Pharmacognostical, Pharmaceutical and HPTLC standards for *Balachaturbhadra Churna*. Organoleptic characters observed for *Balachaturbhadra Churna* were light brown colour, spicy pungent odour, *Kashaya - Tikta* (astringent – bitter) taste and fine consistency of the powder. Powder microscopy shows striking characters of all 4 individual constituents. Starch grains without hilum, dark brown colouring matter, annular vessels and lignified fibres of *Musta*, starch grains without hilum, stone cells and oil globules form *Pippali*, simple and compound starch grains, cork cells, prismatic crystals of *calcium oxalate* and *parenchyma* cells from *Ativisha*, tannin content material, fragments of pitted vessels, vascular bundles along with tannin cells and epidermal cells from *Karkatashringi*.

Loss on drying, ash value, water soluble extract %w/w, alcohol soluble extracts %w/w, pH value of *Balachaturbhadra Churna* were 4.7%w/w, 5.75%w/w, 29.3%w/w, 27.3%w/w and 6 respectively. Particle size of *Churna* was ranging from 60-120 mesh. 3.209g, 2.345g, 1.360g, and 3.019g was obtained from >60, 61-85, 86-120 and >120 mesh respectively.

Qualitative test for various functional groups revealed the presence of carbohydrates, steroids, cardiac glycosides, flavanoids, alkaloids and tannins in the formulations. Saponin was absent in *Churna*. On performing HPTLC, the chromatogram showed 17 peaks with Rf values at 254nm; while at 366nm the chromatogram showed 14 spots. Commonly seen Rf values at both 254nm and 366nm were 0.14, 0.18, 0.23, 0.29, 0.34, 0.35, 0.47, 0.53, and 0.58.

3. Toxicity study

Parmar Parag *et.al.*, in 2011 conducted studies on acute toxicity study on albino rats. Acute toxicity study was carried out as per WHO guideline for acute toxicity test and modified as per experimental need (Anonymous, 1993). The rats were observed closely for behavioural changes, sign and symptoms of toxicity and mortality continuously for the first four hours and thereafter periodically up to 14 days. *Balachaturbhadrika Churna* did not produce any signs and symptoms of toxicity and mortality up to a dosage of 2000 mg/kg in rats.

Nariya M. *et.al.*, in 2011 published data related toxicological study of *Balachaturbhadrika Churna*. The study was carried out by administering *Balachaturbhadrika Churna* in a dose up to 2000 mg/kg orally once. For long-term toxicity, *Balachaturbhadrika Churna* was administered in doses of 450 and 900 mg/kg orally for

45 consecutive days. The effects of the drug on ponderal changes, hematological, biochemical and histological parameters were noted.

The acute toxicity experiment showed that the drug did not produce any signs and symptoms of toxicity (or mortality) up to the dose of 2000 mg/kg. This dose is more than 20 times the therapeutic equivalent dose in rats, clearly indicating that the formulation is unlikely to induce any drastic toxic effects. Long-term toxicity results showed that, even at higher dose of 900 mg/kg, *Balachaturbhadrika Churna* did not affect the parameters studied to a significant extent.

The effect of *Balachaturbhadrika Churna* was studied on bone marrow cellularity. The test drug did not affect the polychromatic normoblasts, erythrocytes and normoblast showing micronuclei at both the dose levels studied, in comparison to the control group. This suggests that it is not likely to have any mutagenicity potential. The histopathological studies of 16 organs showed that *Balachaturbhadrika Churna* at 450 g/kg increased the cellularity in the thymus and spleen. Other organs exhibited normal cytoarchitecture suggesting that the preparation is devoid of serious organ degenerative potential at this dose level.

4. Pharmacological study pertaining to its efficacy

Parmar Parag *et.al.* also conducted studies on cell mediated immunity,

antibody formation and relative weight of spleen and the thymus of albino rats (Parmar, *et.al.*, 2011). For cell mediated immunity *Balachaturbhadrika Churna* at dose of 100 mg/kg and 200 mg/kg produced statistically significant changes on comparison with control group at 24 and 48 hours. Thus it can be inferred that the test drug produces significant suppression of cell mediated immunity.

Balachaturbhadrika Churna did not affect antibody formation against Sheep RBC at significant level. Examination of spleen and thymus sections under microscope showed increase in features of increased cellularity. Though increased cellularity of thymus and spleen along with increased proportion of white pulp was observed, it does not seem to indicate immune stimulation rather it may be the tissue response to the CMI suppression observed with the test drug.

5. Clinical studies conducted to assess its efficacy

No study has been published till now to assess the clinical efficacy *Balachaturbhadra Churna*.

Discussion

An overview of the classics of *Ayurveda* throws light into the specific features of a child, which make them a subject for special considerations. The descriptions given in different contexts include *Dosha Dushya Malalpata* (quantitative and qualitative wise less

Dosha, Dushya, Mala), *Soukumaryata* (delicate by nature), *Alpakayata* (lower body mass index compared to adults), *Sarvannanupa Sevana* (not consuming all types of food), *Aparipakwa Dhatu* (immature state of *Dhatu*), *Asampurna Bala* (inadequate immunity), *Kleshahishnutwa* (unable to withstand hardships), *Ahara Sankarat Aniyatagni* (unstable status of *Agni* as not acclimatized with different states of food materials) and *Asamatvagata Prana Dosha Dhatu Maloujasam* (unstable functional and structural entities in children) (Samhita, *et.al.* 2009, Vagbhata *et.al.*, 2005, Agnivesha *et.al.*, 2009, Vridhhajeevaka, *et.al.* 2009).

All these postulations give a clear idea about the *Dehabala* (body strength), *Agnibala* (strength of digestive fire) and *Satwabala* (mental status) of the pediatric age group. Moreover they provide an idea about the lowered immune status of the child that makes them more susceptible for repeated infections. Another aim behind these considerations is that the child cannot tolerate all forms of medicaments and many of the treatment procedures, so these aspects are to be well considered in the planning and implementation of treatment protocol. *Balachaturbhadra Churna* is one such formulation mentioned in classics specially meant for use in pediatric practice.

Chakrapani Dutta, the famous

commentator on *Charaka Samhita* as well as *Sushruta Samhita*, in text *Chakradatta* mentioned the combination *Balachaturbhadra Churna* for the first time (Chakradatta *et.al.*, 1976). Later to him almost all the renowned texts of Ayurveda including two from the famous *Laghutrayees* have described *Balachaturbhadra Churna* in their texts. The term *Balachaturbhadrika* has been used for *Balachaturbhadra Churna* in *Bhaishajya Ratnavali* (Dasa, 1983). There is no controversy regarding the constituents of *Balachaturbhadra Churna* mentioned in all texts of Ayurveda. The combination of these four drugs is unchanged in all these texts indicating the therapeutic effectiveness of this particular combination in pediatric disorders.

Total five works related to *Balachaturbhadra Churna* which are published till now, were compiled in this work.

Organoleptic studies reveal fine consistency, brownish appearance and bitter taste of the *Churna* (powder). All the studies of *Churna* which were analysed for Pharmacognosy were found having characters of all individual constituents. Striking characters like lignified fibres of *Musta*, starch grains without hilum from *Pippali*, cork cells, *parenchyma* cells from *Ativisha* were observed in all samples.

Physical parameters like bulk density, tap density, Carr's index, Hausner's ratio and angle of repose

showed better flow property of *Balachaturbhadra Churna*. The loss on drying of any sample is directly related to its moisture content. The less value of moisture content could prevent bacterial, fungal or yeast growth (African pharmacopoeia, 1986). The values obtained in all studies were in accordance to the API standards (Anonymous, 2008). The ash value indicates the presence of inorganic and salt materials in the sample. The values obtained for all samples of *Balachaturbhadra Churna* were as per API standards except for one study by Ajazuddin et al. where it was partially higher (Saraf, 2012). This may be due to various factors involved right from cultivation of drug till manufacture of final product.

All the studies show high water-soluble and alcohol soluble extractive values. This indicates the amount of active constituent and the bioavailability of the plant, in given amount of plant material when extracted with respective solvents. The pH of *Balachaturbhadra Churna* was found acidic. Phyto-chemical screening reveals the presence of carbohydrates, steroids, glycosides, flavanoids, alkaloids, phenols and tannins in the formulations. Saponins is absent in *Churna*.

The *Balachaturbhadra Churna* did not modify humoral antibody formation, relative weight of spleen and the thymus of albino rats to

significant extent. Immunological odema represents cell mediated immune response hence it can be inferred that the *Balachaturbhadra Churna* produces significant suppression of cell mediated immunity which is direct correlation of delayed type hypersensitivity (DTH) response and do not influence humoral immune response. The observed effect may be the main mechanism for the efficacy of the drug in respiratory disorders (Parmar, *et.al.*, 2011). The acute and chronic toxicity experiments showed that the drug did not produce any signs and symptoms of toxicity even at very high dosages, which clearly indicates that the formulation is unlikely to induce any drastic toxic effect in spite of containing *Aconitum* species which is known for cardio-toxic and neurotoxic potential. The study on the effect of *Balachaturbhadra churna* on bone marrow cellularity suggests that it is not likely to have any mutagenicity potential (Nariya, *et.al.*, 2011).

Conclusion

No clinical study has been published so far on this classical *Ayurveda* formulation. The doses employed for these toxicity studies as mentioned in pharmacology study were several times higher than normal clinical doses of *Balachaturbhadra Churna*, hence the observed changes will probably not become apparent at therapeutic dose level. This

undoubtedly solves the safety concerns related to the presence of Aconitum species drug in the formulation. Thus

Balachaturbhadra Churna can be considered safe for clinical use.[]

References

- Abhishek Joshi, Aparna K, Rajagopala S, K. S. Patel, C.R. Harisha and V. J. Shukla. Pharmacognostical and Pharmaceutical Assay of Balachaturbhadra churna - A Compound Ayurvedic Formulation. International Journal of Pharmaceutical & Biological Archives 2013; 4(1): 170-174.
- Acharya Sodhala, Gada Nigraha, Tripathi I. and Pandeya G. S. editor. Varanasi: Chaukhambha Samskrta Samsthana; 1994. p. 526.
- African pharmacopoeia. General methods for analysis. Vol.2 (OAU/STRC) Lagos; 1986. P. 123.
- Agnivesha, Charaka Samhita, Chakrapani commentary, Yadavji Trikamji Acharya editor. Varanasi: Chaukhambha Sanskrit Sansthan; 2009, Chikitsa Sthana, Yonivyapat Chikitsa Adhyaya (30/282).
- Ajazuddin, Shailendra Saraf. Development of Fingerprinting Methods of Balacaturbhadraka Churna An Ayurvedic Formulation. Pharmacog Journal 2012; Volume 4, Issue 27:20–24.
- Anonymous, Bhaishajya Samhita, Gujarat Rajya Bhaishajya Samiti. Ahmedabad: Published by Health Ministry, Gujarat; 1960. p. 562
- Anonymous, Research Guidelines for Evaluating the Safety and Efficacy of Herbal Medicines. WHO, Regional Office, Western Pacific Region, Manila, Philippines; 1993.
- Anonymous, The Ayurvedic Pharmacopoeia of India, part 2, Vol.1, 1st ed. New Delhi: Department of AYUSH, Ministry of Health and Family Welfare, Government of India; 2008. p. 43
- Anonymous, The Ayurvedic Formulary of India, Part-I, Govt. India, Ministry of Health and Family Planning, Dept. of Health, India; 1998. p. 92.
- Bhavamishra, Bhavaprakasha. Mishra B. editor. Varanasi: Chaukhambha Samskrta Samsthana; 1980. p. 808.
- Chakradatta, Chakrapanidatta, Tripathi, J. P. editor. Varanasi: Chaukhambha Saubharati Prakashan; 1976. p. 523.
- Govinda Dasa, Bhaishajya Ratnavali, Shastri A. editor. Balarogadhikara, Varanasi: Chaukhambha Samskrta Samsthana; 1983. p.747.
- Jain, C. and Sharma, P. Abhinav Balatantra. Varanasi: Chaukhambha Saurbharati Prakashan; 1990. p. 142.
- M V Viswanathan, P M Unnikrishnan, Katsuko Komatsu, Hirotohi Fushimi and Purusotam Basnet. A brief introduction to Ayurvedic system of medicine and some of its problems. Indian Journal of Traditional Knowledge 2013; 2(2): 159-169
- Mukeshkumar B. Nariya, Parag Parmar, Vinay J. Shukla, B. Ravishankar. Toxicological study of Balachaturbhadra churna. Journal of Ayurveda and Integrative medicine 2011; vol.2, issue 2:P.79-84.
- Parag Parmar, Mukeshkumar B. Nariya, Vinay J. Shukla and B. Ravishankar. Immunomodulatory activity of Balacaturbhadraka churna—An Ayurvedic formulation. J. Med. Pharma. Sci 2011;1(2): p. 10-14.

- Raja Radhakantadeva, Shabda Kalpa Druma. Varanasi: Chaukhambha Sanskrit series; 1961, part 3. p. 451.
- Sarangadharacharya, Sarangadhara Samhita, Sharma P. editor. Varanasi: Chaukhambha Amarabharti Prakashan; 1985. p. 172-175.
- Shah, N. C. Bharat Bhaishajya Ratnakar, Vol. II, Unja: Motilal Banarasidas Publication; 1937. p. 131.
- Shahebaz N. Ghadiyali, Nitesh Patel, Nikunj Trivedi, Hetal Desai. Development of Evaluation Parameters for Balchaturbhadra Churna & comparison with Market Formulation, International Journal of Pharmaceutical Research & Allied Sciences, Volume 1, issue 4 (2012), P.75-84.
- Sharma P. V., Dravyaguna Vijnana. Varanasi: Chaukhambha Bharti Academy; 2001, Vol.-2. (Musta p.371; Pippali p.277; Ativisha p.356; Karkatashringi p.285).
- Shastri Sadashiva, Yoga Ratnakara, Shastri B. and Shastri L. editor. Varanasi: Chaukhambha Samskrta Samsthana; 1973. p. 441.
- Thomas Y.K. Chan. Aconite poisoning. Clinical Toxicology 2009; Vol. 47, No. 4: 279-285.
- Vagbhata, Asthanga Hridaya, Arunadatta and Hemadri commentary, Harishastri Paradakara Vaidya editor. Varanasi: Chaukhambha Orientalia Publications; 2005, Uttara Sthana, Balamaya Pratisheda Adhyaya (2/31). p. 781.
- Vridhhajeevaka, Kashyapa Samhita. Pandit Hemaraja Sharma editor. commented by Satyapala Bhisgacharya. Varanasi: Chaukhambha Sanskrit Sansthan; 2009, Khila Sthana, Bhaishjyopakramaniya Adhyaya (3/82, 83). p. 246.
- Vridhhajeevaka, Kashyapa Samhita. Pandit Hemaraja Sharma editor. commented by Satyapala Bhisgacharya. Varanasi: Chaukhambha Sanskrit Sansthan; 2009, Khila Sthana, Bhaishjyopakramaniya Adhyaya (3/59). p. 245.
- WHO, General guidelines for methodologies on research and evaluation of traditional medicine. World Health Organization. Geneva; 2000.